China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has entered into a strategic partnership with fellow domestic company MGI Tech Co., Ltd (SHA: 688114), a gene sequencing specialist. The collaboration aims to promote the clinical application and global business development of oncology precision medicine, with a focus on regulatory filing and hospital – side business, by leveraging MGI’s core DNBSEQ sequencing technology. Financial terms of the deal were not disclosed.
Partnership Objectives
The partnership is designed to utilize MGI’s advanced DNBSEQ series products, which are known for their leading data utilization, sequencing depth, sequencing time, detection quality, and flexible sample data volume. These features will be harnessed to empower the research and development of cancer diagnosis products and provide more cutting – edge oncology next – generation sequencing (NGS) diagnostics in clinical settings.
Company Profiles
Burning Rock Ltd is a prominent player in the medtech space, focusing on oncology – related diagnostic solutions. MGI Tech Co., Ltd specializes in gene sequencing and its DNBSEQ technology has gained recognition for its performance advantages. The alliance between the two companies is expected to create synergies in the field of oncology precision medicine.
Industry Significance
The move comes as the global oncology precision medicine market is growing rapidly. The partnership between Burning Rock and MGI Tech is seen as a step towards enhancing China’s presence in this field and potentially expanding the reach of advanced oncology diagnostic products both domestically and internationally.-Fineline Info & Tech
Leave a Reply